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Abstract
Rett syndrome (RTT) is a neurodevelopmetal disorder associated with mutations in the methyl-CpG–binding protein 2
(MeCP2) gene. MeCP2-deficient mice recapitulate the neurological degeneration observed in RTT patients. Recent studies
indicated a role of not only neurons but also glial cells in neuronal dysfunction in RTT. We cultured astrocytes from MeCP2-
null mouse brain and examined astroglial gene expression, growth rate, cytotoxic effects, and glutamate (Glu) clearance.
Semi-quantitative RT-PCR analysis revealed that expression of astroglial marker genes, including GFAP and S100b, was
significantly higher in MeCP2-null astrocytes than in control astrocytes. Loss of MeCP2 did not affect astroglial cell
morphology, growth, or cytotoxic effects, but did alter Glu clearance in astrocytes. When high extracellular Glu was added
to the astrocyte cultures and incubated, a time-dependent decrease of extracellular Glu concentration occurred due to Glu
clearance by astrocytes. Although the shapes of the profiles of Glu concentration versus time for each strain of astrocytes
were grossly similar, Glu concentration in the medium of MeCP2-null astrocytes were lower than those of control astrocytes
at 12 and 18 h. In addition, MeCP2 deficiency impaired downregulation of excitatory amino acid transporter 1 and 2
(EAAT1/2) transcripts, but not induction of glutamine synthetase (GS) transcripts, upon high Glu exposure. In contrast, GS
protein was significantly higher in MeCP2-null astrocytes than in control astrocytes. These findings suggest that MeCP2
affects astroglial genes expression in cultured astrocytes, and that abnormal Glu clearance in MeCP2-deficient astrocytes
may influence the onset and progression of RTT.
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Introduction
Rett syndrome (RTT) is a neurodevelopmetal disorder that
affects one in 15,000 female births, and represents a leading cause
of mental retardation and autistic behavior in girls [1,2].
Mutations in the methyl-CpG–binding protein 2 (MeCP2) gene,
located in Xq28, have been identified as the cause for the majority
of clinical RTT cases [3]. Knockout mouse models with disrupted
MeCP2 function mimic many key clinical features of RTT,
including normal early postnatal life followed by developmental
regression that results in motor impairment, irregular breathing,
and early mortality [4,5,6]. MeCP2 dysfunction may thus disrupt
the normal developmental or/and physiological program of gene
expression, but it remains unclear how this might result in a
predominantly neurological phenotype.
In several RTT mouse models, a conditional knockout that is
specific to neural stem/progenitor cells or postmitotic neurons
results in a phenotype that is similar to the ubiquitous knockout,
suggesting that MeCP2 dysfunction in the brain and specifically in
neurons underlies RTT [1,6,7]. Recent studies have demonstrated
that mice born with RTT can be rescued by reactivation of
neuronal MeCP2 expression, suggesting that the neuronal damage
can be reversed [1,6]. In addition, several studies using in vitro cell
culture systems also indicate that MeCP2 may play a role in
processes of neuronal maturation including dendritic growth,
synaptogenesis, and electrophysiological responses [1,7]. These
data support the idea that MeCP2 deficiency in neurons is
sufficient to cause an RTT-like phenotype. However, emerging
evidence now indicates that MeCP2 deficiency in glia may also
have a profound impact on brain function [8,9,10,11,12,13]. Brain
magnetic resonance (MR) studies in MeCP2-deficient mice
demonstrated that metabolism in both neurons and glia is affected
[8]. Furthermore, in vitro co-culture studies have shown that
MeCP2-deficient astroglia non-cell-autonomously affect neuronal
dendritic growth [9,10]. In addition, MeCP2-deficient microglia
cause dendritic and synaptic damage mediated by elevated
glutamate (Glu) release [11]. Very recent studies have indicated
that re-expression of MeCP2 in astrocytes of MeCP2-deficient
mice significantly improves locomotion, anxiety levels, breathing
patterns, and average lifespan, suggesting that astrocyte dysfunc-
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phenotypic regression of RTT [13].
Astrocytes regulate the extracellular ion content of the central
nervous systems (CNS); they also regulate neuron function, via
production of cytokines, and synaptic function, by secreting
neurotransmitters at synapses [14,15]. Moreover, a major function
of astrocytes is efficient removal of Glu from the extracellular
space, a process that is instrumental in maintaining normal
interstitial levels of this neurotransmitter [16]. Glu is a major
excitatory amino acid; excess Glu causes the degeneration of
neurons and/or seizures observed in various CNS diseases [14,17].
RTT is also associated with abnormalities in Glu metabolism, but
these findings are controversial due to the limitations of the
experimental strategies used. Two studies have demonstrated that
Glu is elevated in the cerebrospinal fluid (CSF) of RTT patients
[18,19]. MR spectroscopy in RTT patients also revealed
elevations of the Glu and Gln peak [20,21]. On the other hand,
an animal MR study reported that the levels of Glu and Gln were
decreased in a mouse model of RTT [8]. A more recent study
indicated that MeCP2-null mice have reduced levels of Glu, but
elevated levels of Gln, relative to their wild-type littermates [22].
Another study reported increased Gln levels and Gln/Glu ratios in
Mecp2 mutant mice, but no decreases in Glu levels [23]. Although
these in vivo studies have explored the hypothesis that the Glu
metabolic systems might be altered in RTT, no solid conclusions
have yet been reached [24,25].
In this study, we investigated the contribution of MeCP2 to the
physiological function of astrocytes. Our studies demonstrate that
MeCP2 is not essential for the growth and survival of astrocytes,
but is involved in astrocytic Glu metabolism via the regulation of
astroglial gene expression.
Results
Characterization of MeCP2-null astrocytes
It was recently reported that MeCP2 is normally present not
only in neurons but also in glia, including astrocytes, oligodenro-
cytes, and microglia [9,10,11]. To determine the roles of MeCP2
in astrocytes, we cultured cerebral cortex astrocytes from both
wild-type (MeCP2
+/y) and MeCP2-null (MeCP2
2/y) mouse brains
(Fig. 1). MeCP2-null astrocytes exhibited a large, flattened,
polygonal shape identical to that of the wild-type astrocytes,
suggesting that normal patterns of cellular recognition and contact
were present. Semi-quantitative RT-PCR using primer sets that
specifically amplify two splice variants, Mecp2 e1 and e2, showed
that control astrocytes expressed Mecp2 e1 and e2, whereas
neither Mecp2 variant was detectable in MeCP2-null astrocytes
(Fig. 1A). We further confirmed expression of MeCP2 by
immunocytochemical staining of astrocytes. In control samples,
almost all GFAP-positive cells exhibited clear nuclear MeCP2
immunoreactivity in astrocytes, but no immunoreactivity was
observed in MeCP2-null astrocytes (Fig. 1B).
MeCP2 has been reported to be involved in regulation of
astroglial gene expression [26,27]. Consistent with this, GFAP
levels were significantly higher in MeCP2-null astrocytes (Fig. 1A).
Similarly, the expression of S100b, another astrocyte maturation
marker, was significantly upregulated by MeCP2 deficiency (fold
change of control=1.0, GFAP: 2.19560.504, n=4 each, p,0.05;
S100b: 2.77960.329, n=4 each, p,0.01). These results show that
MeCP2 deficiency upregulates astroglial gene expression in
astrocytes.
To compare the growth of the wild-type and MeCP2-null
astrocytes, we counted total cell number at each passage (Fig. 2A).
As passage number increased, the cell growth rate decreased
dramatically for both types of astrocytes, ultimately culminating in
senescence. There was no significant difference in growth rate
between the control and MeCP2-null astrocyte cultures. We then
measured astrocyte proliferation via BrdU incorporation assay
(Fig. 2B and Fig. S1). After 2 h of BrdU treatment, the proportions
of BrdU-incorporating cells were similar in the control and
MeCP2-null astrocytes (6.63561.655% in control versus
6.77462.272% in MeCP2-null astrocytes, n=4 each, p=0.962).
These results suggest that the absence of MeCP2 did not affect the
proliferation of astrocytes in our culture condition.
We also tested the cytotoxic effects of hydrogen peroxide
(H2O2), ammonium chloride (NH4Cl), and glutamate (Glu), on
astrocytes in our culture (Fig. 2C–E). In cultures derived from both
wild-type and MeCP2-null strains, cell viability decreased with
increasing concentrations of H2O2 and NH4Cl. In contrast, in our
culture conditions, we observed virtually 100% viability of both
the control and MeCP2-null astrocytes after 24 h incubation with
10 mM Glu. Glu-induced gliotoxic effects have been previously
reported by Chen et al. (2000), and are probably due to distinct
differences in culture conditions, specifically the presence of
glucose [28]. These results showed that H2O2 and NH4Cl had a
similar effect in both strains of astrocytes. There was no significant
difference in viability between the control and MeCP2-null
astrocyte cultures, indicating that MeCP2 deficiency did not affect
astrocyte viability upon treatment with H2O2 and NH4Cl.
Effects of glutamate on glutamate transporters and
glutamine synthetase transcripts in MeCP2-null
astrocytes
High extracellular Glu interferes with the expression of the
astrocyte transporter subtypes, excitatory amino acid transporter
1(EAAT1)/glutamate/aspartate transporter (GLAST) and
EAAT2/glutamate transporter-1 (GLT-1) [16,29]. To explore
the effects of Glu on the expression of Glu transporter genes in
cultured astrocytes from wild-type and MeCP2-null mouse brains,
we asked whether treatment with 1.0 mM Glu altered expression
of EAAT1 and EAAT2 mRNA, using a semi-quantitative RT-
PCR assay (Fig. 3). EAAT1 and EAAT2 mRNA were expressed in
both wild-type and MeCP2-null astrocytes, and were slightly
higher in controls than in MeCP2-null astrocytes. Both EAAT1
and EAAT2 mRNA levels were altered in the control astrocytes
after treatment with 1.0 mM Glu. EAAT1 mRNA levels
decreased significantly in the wild-type astrocytes, both 12 h and
24 h after treatment with Glu (Fig. 3A). In contrast, EAAT1
decreased significantly in the MeCP2-null astrocytes, at 12 h but
not 24 h after treatment. As with EAAT1, EAAT2 mRNA levels
also decreased significantly in the control astrocytes, both 12 h and
24 h after treatment (Fig. 3B). However, EAAT2 decreased
significantly in MeCP2-null astrocytes, 24 h but not 12 h after
treatment. In addition, the effects of Glu on EAAT1 and EAAT2
relative fold expression at 12 h were altered in the MeCP2-null
astrocytes (Fig. 3D: EAAT1; 0.61860.033 in control versus
0.75860.049 in MeCP2-null astrocytes, n=10 each, p,0.05;
Fig. 3E: EAAT2; 0.79460.055 in control versus 0.96460.048 in
MeCP2-null astrocytes, n=8 each, p,0.05). These results suggest
that the loss of MeCP2 leads to transcriptional dysregulation of
these genes, either directly or indirectly.
One important enzyme that plays a role in the Glu metabolic
pathway is glutamine synthetase (GS) [17,29]. GS is mainly
located in astrocytes; cultured astrocytes response to Glu with
increased GS expression [17,29]. Consistent with this, 1.0 mM
Glu treatment stimulated GS mRNA expression in both the wild-
type and MeCP2-null astrocytes about 1.2-fold after 12 h but not
24 h (Fig. 3C). In addition, MeCP2 deficiency did not modify the
Characterization of MeCP2-Deficient Astrocytes
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35354effects of Glu on GS mRNA relative fold expression in cultured
astrocytes (Fig. 3F, 1.24560.054 in control versus 1.26560.093 in
MeCP2-null astrocytes, n=6 each, p=0.859). These results
suggested that MeCP2 did not modify the expression of GS in
the cultured astrocytes. Overall, the expression levels of GS
mRNA did not differ between both strains of astrocytes following
treatment with Glu.
Comparison of glutamate clearance between wild-type
and MeCP2-null astrocytes
Because MeCP2 contributed to the transcriptional regulation of
Glu metabolism-related genes in our culture systems, we next
compared the Glu clearance capability of the wild-type and
MeCP2-null astrocytes (Fig. 4A). The cell culture supernatants in
both astrocyte cultures were collected at 3–24 h post incubation in
culture media containing 1.0 mM Glu. After incubation in culture
medium containing Glu, we identified a time-dependent reduction
in Glu over 24 h of incubation in both strains of astrocytes.
Although the shapes of the profiles of Glu concentration versus
time for each strain of astrocytes were grossly similar, Glu
concentration in the medium of MeCP2-null astrocytes were lower
than those of control astrocytes at 12 and 18 h (12 h: control,
0.51360.052 mM versus MeCP2-null, 0.39560.022 mM,
p,0.05; 18 h: control, 0.36860.029 mM versus MeCP2-null,
0.12560.007 mM, p,0.01, n=6 each, Fig. 4A). The differences
in Glu clearance were not due to changes in cell death of control
astrocytes upon application of Glu (Fig. 2E). This indicates that
Glu clearance by MeCP2-null astrocytes was more efficient than
by control astrocytes.
The Glu transporters EAAT1 and EAAT2 are located primarily
on astrocytes and arecritical in maintaining extracellularGluat safe
levels [16]. Threo-beta-benzyloxyaspartate (TBOA) is a broad-
spectrum glutamate transporter antagonist, affecting EAAT1 and
EAAT2 [30]. UCPH-101 (2-amino-4-(4-methoxyphenyl)-7-
(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-car-
bonitrile) and dihydrokainate (DHKA) are selective inhibitors for
EAAT1 and EAAT2, respectively [30,31]. To investigate the
functional Glu transporters in our astrocyte cultures, we analyzed
three Glu transporter blockers (TBOA, UCPH-101, or DHKA)
for their ability to alter the effects of Glu clearance (Fig. 4B–D).
Glu clearance by the wild-type astrocytes was partially blocked
by addition of TBOA and UCPH-101, but not DHKA. This
suggests that EAAT1, but not EAAT2, plays a major role in Glu
clearance under our astroglial culture conditions.
Effects of glutamate on glutamine synthetase and EAAT1
protein in MeCP2-null astrocytes
The initial set of experiments aimed to determine whether Glu
modulate the translation of GS and EAAT1 protein (Fig. 5 and
Fig. S2). GS protein was expressed in both wild-type and MeCP2-
null astrocytes, and was significantly more abundant in MeCP2-
null astrocytes (Fig. 5B: fold change of control=1.0, 2.63160.368,
p,0.01). After 12 h exposure to 0.01–1.0 mM Glu, wild-type
astrocytes exhibited a dose-dependent increase in GS protein
levels (about 6-fold in 1.0 mM Glu treatment). Similar to its effect
on the wild-type astrocytes, in the MeCP2-null astrocytes Glu
exposure dose-dependently increased GS protein levels relative to
untreated astrocytes (Fig. S2). We then examined the effect of
1.0 mM Glu on levels of GS protein, over a time course (Fig. 5A).
GS expression was highest after 12 h exposure to 1.0 mM Glu,
decreasing slightly by 24 h in both wild-type and MeCP2-null
astrocytes. Densitometric analysis of the bands in three indepen-
dent experiments demonstrated that GS protein in MeCP2-null
astrocyte cultures was higher than in wild-type astrocytes, 12 h but
not 24 h after treatment (Fig. 5B: fold change of control=1.0, at
12 h: 1.42160.139, p,0.05; at 24 h: 1.13160.130, p=0.354,
n=4 each). These results indicated that MeCP2 deficiency caused
higher expression of GS protein in cultured astrocytes.
We also asked whether treatment with 1.0 mM Glu altered
expression of EAAT1 protein. EAAT1 protein was expressed in
Figure 1. Characterization of assay cultures. A. Expression of astroglial genes in primary cultured cortical astrocytes. Semi-quantitative RT-PCR
analysis of Mecp2 and astroglial genes was performed in wild-type (white column) and MeCP2-null (gray column) astrocytes. Mecp2 e1 and e2 were
detectable in the wild-type astrocytes. The lower graphs show that the GFAP/HPRT or S100b/HPRT expression ratio in each genotype was normalized
against the level in control astrocytes. Bars represent the means 6 standard errors (SE) of samples from three independent experiments (*p,0.05).
The expression of astroglial markers was significantly upregulated by MeCP2 deficiency. B. Expression of MeCP2 in the primary cultured cortical
astrocytes. The astrocytes were immunostained with MeCP2 (green) and GFAP (red) as glial-specific astrocytic markers. Scale bars indicate 50 mm.
doi:10.1371/journal.pone.0035354.g001
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similar in controls and MeCP2-null astrocytes. EAAT1 protein
levels were altered in the wild-type astrocytes after treatment with
1.0 mM Glu. EAAT1 protein levels decreased significantly in the
wild-type astrocytes, 24 h but not 12 h after treatment (Fig. 5C).
In contrast, EAAT1 did not decrease in the MeCP2-null
astrocytes, either 12 h or 24 h after treatment. In addition, the
relative expression levels of EAAT1 24 h after treatment were
lower in the wild-type than in the MeCP2-null culture, although
the difference was not statistically significant (Fig. 5D: 12 h;
1.10260.169 in control versus 1.09660.142 in MeCP2-null
astrocytes, n=6 each, p=0.979, 24 h; 0.45660.123 in control
versus 0.90160.172 in MeCP2-null astrocytes, n=5 each,
p=0.068). These results suggest that MeCP2 deficiency affects
the expression of GS and EAAT1 protein, and that accelerated
Glu clearance may result from dysregulation of GS and EAAT1
protein in MeCP2-null astrocytes.
Discussion
Recent studies suggest that glia, as well as neurons, cause
neuronal dysfunction in RTT via non-cell-autonomous effects.
Here, we have demonstrated that MeCP2 regulates the expression
of astroglial marker transcripts, including GFAP and S100b in
cultured astrocytes. In addition, MeCP2 is not essential for the cell
morphology, growth, or viability; rather, it is involved in Glu
clearance through the regulation of Glu transporters and GS in
astrocytes. Altered astroglial gene expression and abnormal Glu
clearance by MeCP2-null astrocytes may underlie the pathogen-
esis of RTT.
In this study, MeCP2-null astrocytes exhibited significantly
higher transcripts corresponding to astroglial markers, including
GFAP and S100b. Consistent with this, transcription of several
astrocytic genes, including GFAP, is upregulated in RTT patients
[26,32]. Indeed, MeCP2 binds to a highly methylated region in
the GFAP and S100b in neuroepithlial cells [27,33]; ectopic
Figure 2. Cell growth and viability. A. Comparison of cell growth in wild-type and MeCP2-deficient astrocytes. As passage number increased, cell
growth rate decreased dramatically in both strains of astrocytes. There was no significant difference in growth rate between the control and MeCP2-
null astrocyte cultures. B. Quantification of BrdU-incorporating cells in control and MeCP2-null astrocytes. Astrocytes were cultured for 24 h and
incubated with BrdU for 2 h. The graph shows the percentage of BrdU-incorporating cells in the control (white column) and MeCP2-deficient (gray
column) astrocytes 2 h after BrdU exposure. The number of BrdU-incorporating cells is expressed as a percentage of the total number of Hoechst-
stained cells (Fig. S1). Bars represent the means 6 SE of the samples from four independent experiments. The ratio of BrdU-incorporating cells is
similar in astrocytes taken from both control and MeCP2-null strains. C–E. Comparison of effects of various neurotoxins (C, H2O2; D, NH4Cl; E,
Glutamate) on control and MeCP2-null astrocytes. The graph shows the percentage of viability in the control (white column) and MeCP2-deficient
(gray column) astrocytes after neurotoxin treatment at the indicated concentrations. Bars represent the means 6 SE of samples from three
independent experiments. The glial cultures showed no difference in viability between the control and MeCP2-null strains.
doi:10.1371/journal.pone.0035354.g002
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epithelial cells into GFAP-positive glial cells [34]. Our recent study
in RTT-model ES cells also demonstrated that MeCP2 is involved
in gliogenesis during neural differentiation via inhibition of GFAP
expression [12]. Therefore, MeCP2 may be involved not only in
the suppression of astroglial genes in neuroepithelial cells/neurons
during neurogenesis, but also in the physiological regulation of
astroglial gene expression in astrocytes.
We also demonstrated that MeCP2 is not essential for cell
growth or cell viability in in vitro models of astrocyte injury, such
as H2O2 oxidative stress and ammonia neurotoxicity. On the other
hand, it has been reported that MeCP2 is involved in regulating
astrocyte proliferation, and are probably due to distinct differences
in culture conditions, specifically the presence of serum [10].
Consistent with these results, obvious neuronal and glial
degeneration had not been observed in RTT [6,35]. These
observations suggest that RTT is not caused by reduced cell
numbers, but rather by dysfunction of specific cell types in the
brain.
The regulation of Glu levels in the brain is an important
component of plasticity at glutamatergic synapses, and of neuronal
damage via excessive activation of Glu receptors [15,16].
Astrocytic uptake of Glu, followed by conversion of Glu to
Glutamine (Gln), is the predominant mechanism of inactivation of
Glu once it has been released in the synaptic cleft. This uptake
involves two transporters, EAAT1/GLAST and EAAT2/GLT-1
[16]. Increases in extracellular Glu, present in many brain injuries,
are sufficient to modulate the expression of Glu transporters and
GS [16,29]. Furthermore, application of 0.5–1.0 mM Glu to
cultured cortical astrocytes causes a decline in EAAT1/GLAST
and EAAT2/GLT-1 expression [29]. Our present studies reveal
that 1.0 mM extracellular Glu is sufficient to inhibit astroglial Glu
transporter expression and to stimulate GS expression in control
astrocytes. However, such regulatory influences on Glu transport-
ers are impaired by MeCP2 deficiency. Therefore, MeCP2 may
regulate the expression of Glu transporters under physiological
conditions. Currently, little is known about the promoter regions
of the main Glu transporters [36,37]. Promoter analysis in each
gene may help to elucidate the complex regulations of astroglial
genes by MeCP2.
On the other hand, in our culture conditions, MeCP2 deficiency
did not impair the expression of GS transcripts in cultured
astrocytes, but did affect the expression of GS protein. A very
recent study has shown that defects in the AKT/mTOR pathway
Figure 3. Effect of glutamate on glutamine synthetase and glutamate transporter gene expression in MeCP2-null astrocytes. A–C.
Effects of Glu on Glu clearance-related genes in wild-type (white column) and MeCP2-null (gray column) astrocytes. Semi-quantitative RT-PCR analysis
of Glu clearance-related genes, EAAT1 (A), EAAT2 (B), and GS (C), was performed in the control and MeCP2-null astrocytes 12 or 24 h after treatment
with 1.0 mM Glu. The bands corresponding to PCR products were quantified by densitometry, normalized against HPRT levels, and expressed as % of
controls (equals 100%). Bars represent the means 6 SE of samples from 3–4 independent experiments (*p,0.05, **p,0.01). D–F. Comparison of the
effects of Glu on EAAT1, EAAT2 or GS expression in the control and MeCP2-null astrocytes. The ratio of EAAT1/HPRT (D), EAAT2/HPRT (E) or GS/HPRT
(F) in each treatment group was normalized against that of the non-treated astrocytes from each group. Bars represent the means 6 SE of samples
from 3–5 independent experiments (*p,0.05). Numbers in each column indicate the total number of samples analyzed.
doi:10.1371/journal.pone.0035354.g003
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neuron [38]. These findings suggest that a deficit in protein
synthesis and/or turnover in the MeCP2-null astrocytes might
influence the final levels of GS protein. Further studies are
necessary to investigate whether MeCP2 deficiency impairs the
synthesis and turnover of proteins in RTT.
The most important finding in this study was that MeCP2
deficiency in astrocytes accelerates Glu clearance. Consistent with
this, RTT is associated with abnormalities in the Glu metabolism
[24]. Some studies have demonstrated increases in Glu levels in
the cerebrospinal fluid (CSF) of human RTT patients [18,19]. On
the other hand, in animal studies there have been instances of
decreased Glu levels and/or Glu/Gln ratios, as determined by in
MR spectroscopy [8,21,22,23]. Furthermore, MeCP2-deficient
microglia release an abnormally high level of Glu, causing
excitotoxicity that may contribute to dendritic and synaptic
abnormalities in RTT [11]. These results clearly suggest that
MeCP2 has the potential to regulate Glu levels in the brain under
certain circumstances. Glu levels are altered in the RTT brain, but
the mechanisms responsible for the changes in Glu metabolism are
unknown. In light of our findings, we speculate that abnormal
expression of Glu transporters and GS resulting from MeCP2
deficiency could lead to abnormal Glu clearance in astrocytes and
in turn to altered levels of Glu in RTT brain. Additional studies
are needed to determine the mechanisms underlying changes in
Glu levels and Glu metabolism, and their role in the RTT brain.
In conclusion, MeCP2 modulates Glu clearance through the
regulation of astroglial genes in astrocytes. This study suggests a
novel role for MeCP2 in astrocyte function; these findings may be
useful in exploration of a new approach for preventing the
neurological dysfunctions associated with RTT.
Materials and Methods
Cell culture
For each experiment, primary cultures were generated from
individual MeCP2-null neonates and their wild-type littermates;
tail snips from each neonate were obtained for genotyping, as
described below. Enriched cultures of GFAP-expressing astroglial
cells, which are virtually free of neurons and microglial cells, were
established from the cerebral hemispheres of postnatal day (P) 0 to
P1 newborn mice, as previously described [29]. In brief, pieces of
dissected tissue were trypsinized (0.05%) for 10 min in Ca2
+- and
Mg2
+-free phosphate-buffered saline (PBS) supplemented with
Figure 4. Comparison of glutamate clearance in wild-type and MeCP2-null astrocytes. A. Time-dependent reduction of extracelluar Glu
concentration in wild-type (white column) and MeCP2-null (gray column) astrocyte cultures. After treatment with 1.0 mM Glu, culture supernatant
was collected at the indicated times for the determination of Glu concentration. The graph shows the concentration of Glu in control and MeCP2-null
astrocyte culture medium. Bars represent the means 6 SE of samples from three independent experiments (*p,0.05). B–D. Effects of inhibitors of
glutamate transporters (B, TBOA; C, DHKA; D, UCPH) on Glu clearance. Astrocytes were exposed to the indicated concentration of Glu transporter
inhibitors, and then 0.1 mM Glu was added; culture supernatant was collected for the determination of Glu concentration at 2 h. The graphs show
the clearance ratio upon treatment with each inhibitor. The clearance ratio in the indicated concentration groups was expressed by defining the
control level (no inhibitor) as 1.0. Bars represent the means 6 SE of samples from three independent experiments.
doi:10.1371/journal.pone.0035354.g004
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Hank’s balanced salt solution (HBSS) containing 15% fetal calf
serum (FCS; F2442, Sigma-Aldrich, Inc., St. Louis, MO, USA) by
trituration though 10-ml plastic pipettes. Cells were pelleted at
1006g for 5 min, resuspended in Dulbecco’s modified Eagle’s
medium (D-MEM; Wako Pure Chemical Industries, Ltd., Osaka,
Japan) containing 15% FCS, and seeded into 100-mm culture
dishes previously coated with poly-D-lysine (0.1 mg/ml; Wako
Pure Chemical Industries, Ltd., Osaka, Japan). Upon reaching
confluency, cells were trypsinized and replated. Cells were used
after the third passage (P3) in all experiments, and were seeded at
3610
4 cells/cm
2 in 6-well plate dishes or 35-mm culture dishes.
Cultures were assayed by immunochemical analysis using
antibodies against GFAP, MAP2, and CD11b in order to
determine the degree of enrichment; the astrocyte cultures were
nearly pure without contamination of microglia and neurons (Fig.
S3 and Information S1).
Cell growth and bromo-29-deoxyuridine (BrdU) uptake
assay
To determine growth rate, cells were plated at 2610
5 cells/dish
in 35-mm dishes. At each passage, three dishes per cell line were
harvested by trypsinization, and cell numbers were determined
using a hemocytometer. Growth rate was expressed as the number
of harvested cells divided by the number of seeded cells.
BrdU incorporation during DNA synthesis was determined
using the 5-Bromo-29-deoxy-uridine Labeling and Detection Kit I
(Roche, Indianapolis, IN, USA). Briefly, cells were seeded at
3.0610
4 cells per well in 48-well culture plates and incubated in D-
MEM containing 10% FCS at 37uC for 24 h. After cells were
Figure 5. Effect of glutamate on glutamine synthetase and EAAT1 protein expression in MeCP2-null astrocytes. A. Time-dependent
expression of GS and EAAT1 proteins in wild-type and MeCP2-deficient astrocyte cultures. Astrocytes were treated with 1.0 mM Glu for 24 h, and
subsequently analyzed for expression of GS and EAAT1 by Western blot analysis. Beta-actin protein levels were analyzed in the same way, as an
internal control. B. The immunoreactive GS protein bands were quantified by densitometry, normalized against b-actin levels, and expressed as fold
change relative to the controls (equals 1.0). Bars represent the means 6 SE of samples from three independent experiments (*p,0.05, **p,0.01).
Numbers in each column indicate the total number of samples analyzed. C. The immunoreactive EAAT1 protein bands were quantified by
densitometry, normalized against b-actin levels, and expressed as % of controls (equals 100%). Bars represent the means 6 SE of samples from three
independent experiments (**p,0.01). D. Comparison of the effects of Glu on EAAT1 expression in wild-type and MeCP2-null astrocytes. The ratio of
EAAT1/b-actin in each treatment group was normalized against that of the non-treated astrocytes from each group. Bars represent the means 6 SE of
samples from three independent experiments. Numbers in each column indicate the total number of samples analyzed.
doi:10.1371/journal.pone.0035354.g005
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ethanol in 50 mM glycine (pH 2.0) for 20 min at 220uC. Cells
were incubated with an anti-BrdU monoclonal antibody, followed
by a fluorescein-coupled goat anti-mouse Ig and Hoechst33324
(1 mg/ml). To determine the percentages of BrdU-positive cells,
fluorescent images were obtained by a Biorevo BZ-9000
fluorescence microscope (KEYENCE Co., Osaka, Japan); images
were analyzed using the BZ-II application. BrdU-positive cells and
total cells were counted in random 3 fields per well (approximately
1200 cells per well). Results were obtained from four independent
experiments.
Cell Viability Analysis
Cell were seeded at 1610
4 cells per well in 96-well plates and
incubated in D-MEM containing 15% FCS at 37uC for 24 h. In
injury models of drug and oxidative stress, cells were incubated
with 0.01–10 mM glutamate for 24 h, 12.5–200 mM NH4Cl
(Sigma Chemical Co.) for 4 h, or 0.125–1.0 mM H2O2 (Wako
Pure Chemical Industry, Osaka, Japan) for 1 h as previously
described [28,39,40]. After 24 h of drug treatment, cell viability
was determined using the WST-8 assay (NACALAI TESQUE,
INC., Kyoto, Japan) [39,41].
PCR analysis
MeCP2
2/+ female mice (B6.129P2(C)-Mecp2
tm1.1Bird/J strain)
were purchased from the Jackson Laboratory (Bar Harbor, ME)
and mated with wild-type C57BL/6 male mice. DNA samples
were extracted from tail snips from newborn animals; prior to
nucleic acid extraction, snips were digested with proteinase K.
Genotyping was performed by PCR analysis of genomic DNA
according to the protocol provided by the manufacturer
(http://jaxmice.jax.org/pub-cgi/protocols/protocols.sh?objtype=
protocol&protocol_id=598) [4,12]. All experiments were per-
formed in accordance with the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals, and were
approved by the Animal Research Committee of Kurume
University.
Total RNA was extracted from cells using a Sepazol RNA I
super kit (Nacalai Tesque, Inc., Kyoto, Japan) [41,42]. One
microgram of total RNA was reverse transcribed, and 1/100 of the
cDNA (equivalent to 10 ng of total RNA) was subjected to PCR
amplification with Taq DNA polymerase (Promega, Co., Ltd.,
Madison, WI) using the following conditions: 25–35 cycles of 94uC
for 30 s, annealing temperature for 60 s, and 74uC for 60 s.
Primer sets and annealing temperatures are shown in Table 1. The
most appropriate PCR conditions for semi-quantitative analysis of
each gene were carefully determined by several preliminary
experiments (Fig. S4). The number of cycles for GFAP, S100b,
EAAT1, EAAT2, and GS was 25, 32, 35, 32, and 25, respectively
(Table 1). The amplified cDNA was electrophoresed on 2%
agarose gels containing ethidium bromide, and quantities were
analyzed by densitometry using ImageJ software (the Research
Service Branch of the National Institute of Health, Bethesda, MD,
USA) [42]. The relative expression of each gene was normalized to
the intensity of a housekeeping gene, hypoxantine-phosphoribosyl-
transferase (HPRT; 30 cycles). The expression level of each gene is
reported as a ratio relative to the level of normalized expression in
a control sample.
Immunocytochemistry
Cultures were fixed with 4% paraformaldehyde for 10 min and
permeabilized with 0.05% Triton-X 100 for 5 min. After blocking
of nonspecific binding sites with 10% nonfat dry milk in PBS for
1 h, cultures were immunocytochemically stained using antibodies
against MeCP2 (anti-MeCP2 polyclonal antibody, MILLIPORE,
Temecula, CA, USA; anti-MeCP2 monoclonal antibody, G-6,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA), b-tubulin type
III (TuJ, Sigma-Aldrich, Inc., St. Louis, Missouri), or glial fibrillary
acidic protein (GFAP) (anti-GFAP polyclonal antibody, G9269;
anti-GFAP monoclonal antibody, G3893, Sigma-Aldrich, Inc., St.
Louis, Missouri), followed by secondary fluorescent antibodies as
described previously [12]. Cultures were additionally stained with
Hoechst33342 and examined using an Olympus IX-70 (Olympus
Japan Inc. Tokyo, Japan) microscope. Photomicrographs were
captured using an Olympus DP70 digital camera.
Immunoblotting
Cell extracts were prepared from astroglial cultures as described
previously [41]. Western blot analysis was performed using anti-
glutamine synthetase (G2781; Sigma-Aldrich, Inc., St. Louis,
Missouri), anti-excitatory amino acid transporter 1 (EAAT1,
GLAST; Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
horseradish peroxidase-conjugated anti-rabbit IgG (DakoCytoma-
tion, Glostrup, Denmark), and chemiluminescent substrate
(Chemi-Lumi One, NACALAI TESQUE, INC., Kyoto, Japan)
[12,41]. Several different exposure times were used for each blot to
ensure linearity of band intensities. Immunoreactive bands were
quantified using the ImageJ software (Research Service Branch of
the National Institute of Health, Bethesda, MD, USA). The
relative expression of each protein was normalized to the intensity
of b-actin. The expression level of each protein is reported as a
Table 1. PCR primers.
Sense Antisense Ta cycles
GFAP 59-ATCCGCTCAGGTCATCTTACCC-39 59-TGTCTGCTCAATGTCTTCCCTACC-39 63 25
S100b 59-AGAGGACTCCAGCAGCAAAGG-39 59-AGAGAGCTCAGCTCCTTCGAG-39 59 32
EAAT1 59-GAAGTCTCCCAGACGTTCTAATCC-39 59-GCTCTGAAACCGCCACTTACTATC-39 65 35
EAAT2 59-ATGCTCATCCTCCCTCTTATCATC-39 59-CTTTCTTTGTCACTGTCTGAATCTG-39 63 32
GS 59-TGTACCTCCATCCTGTTGCC-39 59-GTCCCCGTAATCTTGACTCC-39 57 25
HPRT 59-CCTGCTGGATTACATTAAAGCACTG-39 59-AAGGGCATATCCAACAACAA-39 57 30
MeCP2 59-GGTAAAACCCGTCCGGAAAATG-39 59-TTCAGTGGCTTGTCTCTGAG-39 61 35
GFAP, glial fibrillary acidic protein; EAAT, excitatory amino acid transporter; GS, glutamine synthetase; HPRT, hypoxantine-phosphoribosyl-transferase; MeCP2, methyl-
CpG-binding protein 2; Ta, annealing temperature (uC).
doi:10.1371/journal.pone.0035354.t001
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sample.
Glutamate Clearance Assay
To measure extracellular glutamate (Glu) concentrations, we
used the Glutamate Assay Kit colorimetric assay (Yamasa
Corporation, Tokyo, Japan) [43]. Assays were carried out in six
independent trials. The clearance ratio of Glu was calculated from
the Glu concentration (mM) in the medium sample of the drug-
treated astroglial cells (Gludrug) and the control non-drug treated
(i.e., treated with drug vehicle alone) glial cells (Glusolv). This is
represented mathematically as follows: Glu clearance ra-
tio=(1002Gludrug)/(1002Glusolv). Threo-beta-benzyloxyaspartate
(TBOA), UCPH-101 (2-amino-4-(4-methoxyphenyl)-7-(naphtha-
len-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile), or
dihydrokainate (DHKA) (all purchased from Tocris Bioscience
Ellisville, MO, USA) were applied to astroglial cells 60 min before
Glu.
Statistical analysis
Quantitative results are expressed as means 6 standard errors
(SE). Student’s t-test was used to compare data, with p,0.05
considered significant.
Supporting Information
Figure S1 BrdU-incorporating cells in wild-type and
MeCP2-null astrocytes. The top and bottom pictures show
BrdU-incorporating (Green) and Hoechst-stained (Blue) cells,
respectively, which were stained with the primary anti-BrdU
antibodies, the secondary fluorescein-coupled antibodies, and
Hoechst 33324. Negative controls received identical treatments,
but were not exposed to BrdU. Representative pictures were used
to accurately count the number of BrdU incorporated cells to
assess the efficiency of astrocyte cell growth. Scale bar=200 mm.
(EPS)
Figure S2 Concentration dependency of GS and EAAT1
expression in wild-type and MeCP2-null astrocytes
treated with Glutamate. The astrocytes of each group were
treated with 0.01–1.0 mM Glu for 12 h, and subsequently
analyzed for expression of GS and EAAT1 by western blot
analysis.
(EPS)
Figure S3 Purity of astroglial cultures from mouse
brain. The purity of astroglial cultures was assessed by
immunocytochemisty (A) and immunoblotting (B) using antibodies
against glial fibrillary acidic protein (GFAP; astrocyte marker;
Sigma-Aldrich), CD11b (microglial marker; Santacruz), or micro-
tubule associated protein 2 (MAP2; neuronal marker; Sigma-
Aldrich). A. Immunocytochemistry indicates that neither CD11b
nor MAP2 were expressed in astrocyte cultures. Positive control
indicates microglia and mouse ES-derived neural cells that stained
with anti-CD11b and MAP2 antibodies, respectively. Scale
bar=100 mm. B. Western blot analysis of protein extracts from
cultured astrocytes and mouse whole brain. Western blot analysis
also confirmed that the cultured astrocytes expressed GFAP, but
did not express CD11b and MAP2.
(EPS)
Figure S4 Optimization of the semi-quantitative RT-
PCR assay. Total RNA extracted from neonatal mouse brain
astrocytes was serially diluted (2.5, 5, 10, 20, and 40 ng RNA in
lanes 1, 2, 3, 4, and 5, respectively), reverse-transcribed and used
as control samples in semi-quantitative RT-PCR for GFAP (A),
S100b (B), HPRT (C), EAAT1 (D), EAAT2 (E), and GS (F). PCR
was carried out for indicated cycles using each of primer sets
shown in Table 1. The amplified cDNA was electrophoresed in a
2% agarose gel containing ethidium bromide. NT, RT-PCR with
no template.
(EPS)
Information S1 Supporting materials and methods.
(DOC)
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